HPV Vaccine

participate study hpv vaccine

What is HPV?

HPV, or Human Papillomavirus, is a group of more than 200 related viruses, some of which are spread through sexual activity. Sexually transmitted HPV types fall into two main risk groups, low and high risk. Low-risk HPVs usually do not lead to complications. Unfortunately, high risk HPVs can cause several types of cancers. According to the National Cancer Institute, HPV infection is relatively common. In fact, nearly all sexually active people are infected with HPV almost immediately once they become sexually active. Around half of those infections are with a high-risk HPV type which, if the infection persists, can lead to cancer. Sometimes HPV infections are not successfully controlled by one’s immune system. When a high-risk HPV infection persists for many years, it can lead to cell changes that may get worse over time and lead to cancer.

Preventing HPV Infection with HPV Vaccination

HPV vaccination is recommended by the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunizations Practices (ACIP) to prevent new HPV infections and HPV-associated diseases, including some cancers. HPV vaccination provides strong protection against new HPV infections, but the vaccine does not cure and is not used to treat HPV infections or diseases caused by HPV. HPV vaccination offers the most protection when given before someone is exposed to the virus.

HPV Vaccine Study

Dr. James Clark is conducting a clinical trial for healthy male adults who are between the age of 20 and 45 years of age. The purpose of the study is to evaluate the efficacy, safety and the immune response of an HPV vaccine in the prevention of oral persistent HPV infection. The research office will provide study related exams and lab work throughout your participation. Those who are qualified and enrolled will be compensated for time and travel.

For a brief video of HPV and oral cancer, please visit Mayo Clinic HPV Oral Cancer Review.

Dr. James Clark is conducting a clinical trial for healthy male adults who are between the age of 20 and 45 years of age. The purpose of the study is to evaluate the effectiveness, safety and the immune response of an HPV vaccine in the prevention of oral persistent HPV infection. The research office will provide study related exams and lab work throughout your participation. Those who are qualified and enrolled will be compensated for time and travel.

Find out if you qualify

Please fill out the form to see if you qualify. We’ll contact you directly to inquire about your eligibility for this research study.